8th Global Symposium on Ketogenic Therapies

第八届全球生酮疗法研讨会

• 批准号: 10753748
• 负责人: Jong Min Rho
• 金额: $ 2.5万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10753748
• 关键词: Adult; Advocacy; Alzheimer' s Disease; Anniversary; Anticonvulsants; Anxiety; Awareness; Basic Science; Bipolar Disorder; Brain; Budgets; California; Carbohydrates; Clinical; Clinical Investigator; Clinical Research; Cognition Disorders; Collaborations; Communities; Congresses; Country; Dedications; Diet and Nutrition; Diet therapy; Dietitian; Discipline; Disease; Dissemination and Implementation; Eastern Africa; Eastern Europe; Education; Educational workshop; Effectiveness; Eligibility Determination; Epilepsy; Fasting; Fatty Acids; Fatty acid glycerol esters; Fellowship; Fertilization; Formulation; Foundations; Funding; Future Generations; Glucose Transporter; Goals; Grant; Growth; Headache; International; Intractable Epilepsy; Ketone Bodies; Knowledge; Lead; Malignant - descriptor; Malignant neoplasm of brain; Mediator; Medical; Mental Depression; Mental Health; Mental disorders; Metabolic; Metabolism; Modernization; Multiple Sclerosis; Neurologic; Nurses; Parkinson Disease; Patients; Perception; Physicians; Postdoctoral Fellow; Pre-Clinical Model; Professional Organizations; Property; Proteins; Protocols documentation; Randomized; Recording of previous events; Research; Research Personnel; Resources; SLC2A1 gene; Schedule; Schizophrenia; Science; Scientist; Series; Sleep Disorders; Social Workers; Societies; Solid; Southeastern Asia; Standardization; Students; Syndrome; Therapeutic; Time; Training; Translational Research; Travel; United States National Institutes of Health; Variant; autism spectrum disorder; brain metabolism; chronic pain; clinical application; clinical efficacy; dietary; equity, diversity, and inclusion; experience; health application; innovation; interdisciplinary collaboration; interest; ketogenic diet; ketogentic; meetings; neglect; nervous system disorder; neuroprotection; novel; personalized care; posters; pre-clinical; programs; prospective; spinal cord and brain injury; success; symposium; treatment choice

PROJECT SUMMARY The ketogenic diet (KD) is an established medical therapy for drug-resistant epilepsy, and since its origins in 1921 has steadily grown in clinical importance and worldwide implementation. Moreover, the expanding research into the scientific underpinnings of this metabolism-based treatment have highlighted numerous novel mechanisms. Moreover, there is mounting experimental evidence for potential disease-modifying and neuroprotective properties of metabolic substrates such as ketone bodies and fatty acids, such that preclinical and clinical investigators have been exploring broader uses of the KD and its variants in diverse neurological (and even mental health) conditions such as malignant brain cancer, autism spectrum disorder, Alzheimer's disease, and bipolar disorder. Despite proven clinical efficacy and relative affordability compared to anti-seizure medications, large regions of the world still do not and cannot broadly offer KD therapies to eligible patients. Centers often have inadequate resources, as well as a lack of appropriately trained physicians and/or dietitians. Furthermore, the latest research findings may not be well disseminated, and a lack of standardized protocols and management strategies present additional barriers. Without adequate support or proper education, patients may not consider this treatment due to its traditional restrictiveness and myths surrounding its use. Regular regional and international meetings are needed where scientists, physicians, dietitians, nurses, social workers and trainees at all levels can meet and discuss and share protocols, research innovations, clinical experience and establish new collaborations in the growing KD field. The 8th Global Symposium on Ketogenic Therapies (to be held September 17-21, 2023 in San Diego, California) is the latest in a successful and evolving biennial conference series first launched in 2008 with support from a NIH R13 conference grant. There has been an enduring collaborative spirit with a common purpose that has now matured into a new professional society called the International Neurological Ketogenic Society or INKS. The 8th Global Symposium represents another leap forward: the focus remains on promoting collaborative interactions among clinical and basic scientists and trainees and disseminating the latest research to the community and beyond, and a strong emphasis will be placed on standardizing and enhancing international dissemination and implementation – all of this in the spirit of equity, diversity and inclusion. Moreover, this will be the first congress in the biennial series organized in conjunction with two aligned organizations, the Glucose Transporter Deficiency 1 (GLUT1) Foundation and the International Society of Neurogastronomy (ISN). The KD is the treatment of choice for the GLUT1 deficiency syndrome, and ISN's focus on the science and practice of flavor perception represents an often-neglected aspect of diet and nutrition that is central to compliance and success of dietary treatments. These symposia will remain the definitive venue for progress in and advocacy for metabolism-based therapies for neurological disorders.

项目总结 生酮饮食(KD)是一种公认的治疗抗药性癫痫的药物，自从它起源于 1921年在临床上的重要性和在全球范围内的实施稳步增长。此外，不断扩大的研究 这种以新陈代谢为基础的治疗的科学基础突出了许多新的 机制。此外，有越来越多的实验证据表明，潜在的疾病修改和 代谢底物，如酮体和脂肪酸的神经保护特性，使临床前 临床研究人员一直在探索KD及其变种在不同神经学中的更广泛用途 (甚至精神健康)疾病，如恶性脑癌、自闭症谱系障碍、阿尔茨海默氏症 疾病和双相情感障碍。尽管与抗癫痫药相比，已证实的临床疗效和相对可负担性 在药物治疗方面，世界上大部分地区仍然没有也不能广泛地向符合条件的患者提供KD疗法。 中心往往资源不足，而且缺乏受过适当培训的医生和/或营养师。 此外，最新的研究结果可能没有得到很好的传播，而且缺乏标准化的方案 而管理策略也带来了额外的障碍。如果没有足够的支持或适当的教育，患者 可能不会考虑这种治疗方法，因为它的传统限制性和围绕其使用的神话。常规 需要召开区域和国际会议，科学家、医生、营养学家、护士、社会工作者 各级学员可以开会讨论和分享方案、研究创新、临床经验 并在不断增长的KD领域建立新的合作关系。第八届全球生酮疗法研讨会(TO 将于2023年9月17日至21日在加利福尼亚州圣地亚哥举行)是成功和不断发展的两年期中的最新一届 会议系列于2008年首次推出，得到了NIH R13会议拨款的支持。已经有了一个 具有共同目标的持久合作精神，现已成熟为一个新的专业社会，称为 国际神经病酮症学会或墨水。第八届全球研讨会代表着又一次飞跃 展望：重点仍然是促进临床和基础科学家之间的协作互动 和受训人员，并向社区和其他地方传播最新研究成果，并强烈强调 将把重点放在规范和加强国际传播和实施上-所有这些 本着公平、多样性和包容的精神。此外，这将是两年一度的系列会议中的第一次 与两个联合组织葡萄糖转运蛋白缺乏症1(GLUT1)联合组织 基金会和国际神经学学会(ISN)。KD是治疗非小细胞肺癌的首选方法 Glut1缺乏综合症，ISN对味道感知的科学和实践的关注代表了一种 经常被忽视的饮食和营养方面，这是饮食治疗依从性和成功的核心。这些 研讨会将继续是以新陈代谢为基础的治疗进展和倡导的最终场所。 神经紊乱。